Novartis BP drug sees approval in Europe

Share this article:
The European Commission approved Novartis' Rasilez (aliskiren) for use in the European Union.

The approval follows an FDA endorsement earlier this year in the US, where the drug is sold as Tekturna. It's also approved in Switzerland.

Analysts have estimated peak sales of between $2.5 billion to $3.5 billion for the Novartis pill, which was co-developed by Swiss biotech company Speedel.

When used alone, Rasilez demonstrates greater blood pressure lowering than other commonly-used blood pressure medicines, like ACE inhibitors and certain diuretics. When added to existing therapy, it provides additional blood pressure lowering, the company said in a statement.

Novartis said nearly a billion people around the world have high blood pressure, and almost 70% do not reach their blood pressure goal.

Tekturna targets renin, an enzyme responsible for triggering a process that can contribute to the condition.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.